Eli Lilly gets FDA green light for Reyvow

Eli Lilly has received the Food and Drug Administration’s nod for Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

"Reyvow is a new option for the acute treatment of migraine, a painful condition that affects one in seven Americans," said Nick Kozauer, acting deputy director of the division of neurology products in the FDA's Center for Drug Evaluation and Research.

Kozauer added, "We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine."